Evidence map›Paper›PMID 34544218›Full record

ArticleTurkish journal of medical sciences2022

Evaluation of atrial fibrosis in atrial fibrillation patients with three different methods.

Cem Çöteli, Tuncay Hazırolan, Kudret Aytemir, Ahmet Gürkan Erdemir, Emine Nilay Bakır, Uğur Canpolat, Hikmet Yorgun, Ahmet Hakan Ateş, Ergun Barış Kaya, Zeliha Günnur Dikmen and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Turkish journal of medical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Cem ÇöteliDepartment of Cardiology, Ankara City Hospital, Ankara, Turkey.
Tuncay HazırolanDepartment of Radiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Kudret AytemirDepartment of Cardiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Ahmet Gürkan ErdemirDepartment of Radiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Emine Nilay BakırDepartment of Biochemistry, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Uğur CanpolatDepartment of Cardiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey; Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, TX, USA.
Hikmet YorgunDepartment of Cardiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Ahmet Hakan AteşDepartment of Cardiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey; Department of Cardiology, Faculty of Health Medicine and Life Sciences, Maastricht University, Maastricht, Netherland.
Ergun Barış KayaDepartment of Cardiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Zeliha Günnur DikmenDepartment of Biochemistry, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Necla ÖzerDepartment of Cardiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Hacettepe University · TRMemorial Ankara Hospital · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe presence of atrial fibrosis has already been known as a risk factor for atrial fibrillation (AF) development. We aimed to evaluate atrial fibrosis with previously defined three different methods, which were cardiac magnetic resonance imaging (C-MRI), echocardiographic strain imaging, and biomarkers and show the relationship between these methods in patients with AF scheduled for cryoballoon ablation.

methodsA total of 30 patients were enrolled. Atrial T1 relaxation durations were measured using C-MRI before the procedure of atrial fibrillation catheter ablation. Fibroblast growth factor-21 (FGF-21) and fibroblast growth factor-23 (FGF-23) levels were measured at serum derived from the femoral artery (Peripheral FGF 21 and 23) and left atrium blood samples (Central FGF 21 and 23) before catheter ablation. Preprocedural transthoracic echocardiography was performed. The median follow-up duration for atrial tachyarrhythmia (ATa) recurrence was 13 (12-18 months) months.

resultsThe mean ages of the study group were 55.23 ± 12.37 years, and there were 17 (56.7%) female patients in study population. There were negative correlations between post contrast T1 relaxation durations of both posterior and posterosuperior atrium, and central FGF-23 (r: - 0.561; p = 0.003; r:-0.624; p = 0.001; Posterior T1 vs. central FGF-23 levels and Posterosuperior T1 vs central FGF-23 levels, respectively). The positive correlations were observed between postcontrast posterior T1 relaxation durations and left ventricle ejection fraction (r:0.671; p = 0.001); left atrial emptying fraction (r:0.482; p = 0.013); peak atrial longitudinal strain (r:0.605; p = 0.001), and peak atrial contraction strain (r:0.604; p = 0.001). Also negative correlation was observed between postcontrast posterior T1 relaxation durations, and left atrial volume index (r: - 0.467; p = 0.016).

Indexed as

Atrial FibrillationCatheter AblationAdultAgedFemaleFibrosisHeart AtriaHumansMaleMiddle AgedTreatment OutcomeVentricular Function, LeftAtrial fibrillationatrial fibrosisatrial strain imagingcardiac MRI T1 relaxation durationFGF-21FGF-23

Identifiers

PMID34544218
PMCPMC10734846
OpenAlexW3200995928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.